Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010

Osteoporosis International

Volumn 26, Issue 7, 2015, Pages 1919-1928

  Klop, C ^a   Gibson Smith, D ^b   Elders, P J M ^c   Welsing, P M J ^d   Leufkens, H G M ^a   Harvey, N C ^e,f   Bijlsma, J W J ^d   van Staa, T P ^a,h   de Vries, F ^a,e,g,i  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti osteoporotic drugs; Bisphosphonate; Osteoporosis; Osteoporotic fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TREATMENT RESPONSE; UNITED KINGDOM; CLINICAL PRACTICE; CLINICAL TRIAL; COMPLICATION; DRUG UTILIZATION; HIP FRACTURES; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; OSTEOPOROTIC FRACTURES; PRIMARY HEALTH CARE; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HIP FRACTURES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; RECURRENCE; SECONDARY PREVENTION; UNITED KINGDOM;

EID: 84933277407     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3098-x     Document Type: Article

References (51)

1. National osteoporosis society, URL: http://www.nos.org.uk/page.aspx?pid=328 Accessed 22 January 2015
2. Smith P, Ariti C, Bardsley M (2013) Focus on hip fracture: trends in emergency admission for fractured neck of femur, 2001 to 2011. Nuffield Trust/Health Foundation, London
3. Warriner AH, Patkar NM, Yun H, Delzell E (2012) Minor, major, low-trauma, and high-trauma fractures: what are the subsequent fracture risks and how do they vary? Curr Osteoporos Rep 10:22–27
4. von Friesendorff M, Besjakov J, Akesson K (2008) Long-term survival and fracture risk after hip fracture: a 22-year follow-up in women. J Bone Miner Res 23:1832–1841
5. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102
6. Medicines and Healthcare products Regulatory Agency (MHRA)/Committee on Safety of Medicines (2004) Review of the evidence on long-term safety of HRT. Curr Probl Phamacovigilance 30:4–6
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
8. Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65–78
9. Formiga F, Rivera A, Nolla JM, Coscujuela A, Sole A, Pujol R (2005) Failure to treat osteoporosis and the risk of subsequent fractures in elderly patients with previous hip fracture: a five year retrospective study. Aging Clin Exp Res 17:96–99
10. Rabenda V, Vanoverloop J, Fabri V, Mertens R, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 90:2142–2148
11. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305
12. Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29:1929–1937
13. McGowen B, Bennet K, Casey MC, Doherty J, Silke C, Whelan B (2013) Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005–2008. Ir J Med Sci 182:601–608
14. Fisher A, Martin J, Srikusalanukul W, Davis M (2010) Bisphosphonate use and hip fracture epidemiology: ecological proof from the contrary. Clin Interv Aging 5:355–362
15. Fraser LA, Ioannidis G, Adachi JD, Pickard L, Kaiser SM, Pior J et al (2011) Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 22:789–796
16. Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 35:319–326
17. Roerholt C, Eikken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299–307
18. Brauer CA, Coa-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573–1579
19. Alves SM, Economou T, Oliveira C, Ribeiro NN, Gomez-Barrena PMF (2012) Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone 53:430–436
20. Watson J, Wise L, Green J (2007) Prescribing of hormone replacement therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005 Eur J. Clin Pharmacol 63:843–849
21. Reymondier A, Caillet P, Abbas-Chorfa F, Ambrosi V, Jaglal SB, Chapurlat R et al (2013) MENOPOST—calcium and vitamin D supplementation in post-menopausal osteoporosis treatment: a descriptive cohort study. Osteoporos Int 24:559–566
22. Hanley DA, Zhang Q, Meilleur MC, Mavros P, Sen SS (2007) Prescriptions for vitamin D among patients taking antiresorptive agents in Canada. Curr Med Res Opin 23:1473–1480
23. Bayly JR, Hollands RD, Riordan-Jones SE, Yemm SJ, Brough-Williams I, Thatcher M et al (2006) Prescribed vitamin D and calcium preparations in patients treated with bone remodeling agents in primary care: a report of a pilot study. Curr Med Res Opin 22:131–137
24. Royal College of Physicians. Falling standards, broken promises. Report of the national audit of falls and bone health in older people 2010. URL: https://www.rcplondon.ac.uk/sites/default/files/national_report.pdf, assessed 25 Jan 2015
25. Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839–848
26. National Institute for Health and Care Excellence (2008) Technological appraisal (TA)161 Osteoporosis-Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
27. Kanis JA, Mc Closkey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:407–413
28. National Institute for Health and Care Excellence (2005) Technology appraisal (TA)87. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
29. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202
30. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS et al (2003) BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18:1947–1954
31. Wang L, Shawn Tracy C, Moineddin R, Upshur RE (2013) Osteoporosis prescribing trends in primary care: a population-based retrospective cohort study. Prim Health Care Res Dev 14:1–6
32. Peeters G, Tett SE, Duncan EL, Mishra GD, Dobson AJ (2014) Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy. Pharmacoepidemiol Drug Saf 23:1303–1311
33. McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034
34. Zhang J, Delzell E, Curtis JR, Hooven F, Gehlbach SH, Anderson FA, Saag KG (2013) Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass. Osteoporos Int 25:317–324
35. Bessette L, Jean S, Davison KS, Roy S, Ste-Marie LG, Brown JP (2009) Factors influencing the treatment of osteoporosis following fragility fracture. Osteoporos Int 20:1911–1919
36. Wilk A, Sajjan S, Modi A, Fan C-PS, Mavros P (2014) Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA. Osteoporos Int 25:2777–2786
37. Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manage care 7:597–605
38. Beaton DE, Dyer S, Jiang D, Sujic R, Slater M, Sale JEM, Bogoch ER (2014) Factors influencing the pharmacological management of osteoporosis after fragility fracture: results from the Ontario Osteoporosis Strategy’s fracture clinic screening program. Osteoporos Int 25:289–296
39. Duyvendak M, Naunton M, van Roon EN, Brouwers JRBJ (2011) Doctors’ beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention. J Clin Pharm Ther 36:356–366
40. Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X (2010) Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int 21:1427–1436
41. Nayak S, Roberts MS, Chang CC, Greenspan SL (2010) Health beliefs about osteoporosis and osteoporosis screening in older women and men. Health Educ J 69:267–276
42. Jaglal SB, Carrol J, Hawker G et al (2003) How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs. Can Fam Physician 49:462–468
43. Johnson CS, McLeod W, Kennedy L, McLeod K (2008) Osteoporosis health beliefs among younger and older men and women. Health Educ Behave 35:721–733
44. Sedlak CA, Doheny MO, Estok PJ (2000) Osteoporosis in older men: knowledge and health beliefs. Orthop Nurs 19:38–42
45. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Adami J, Graham S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610
46. Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809
47. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–1501
48. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397
49. Compston J, Bowring C, Cooper A, Cooper C, Davies C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P; National Osteoporosis Guideline Group (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update. Maturitas 75:392–6
50. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman S, Singleton R, Siris E (2012) ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27:2039–2046
51. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C, IOF Fracture Working Group (2013) Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 24:2135–2152